Up to now the age group 6 months to five years are the only age group that remains ineligible for vaccination against Covid-19 disease, but according to the United States Food and Drug Administration (FDA), this is about to change.
At the end of February, the FDA could expand the use of the Pfizer/BioNTech Covid-19 vaccine for children between the ages of 6 months to five years of age.
For this, the regulators will have to start reviewing the data focused on this age group and two doses will continue to be used, while the possibility of a third is studied.
Read more: Anti-vaccines allow the Covid-19 virus to continue circulating
Last December, the pharmaceutical company said a trial in children with a third dose of the vaccine was underway because two did not generate a sufficient immune response.
That is why it is thought that the FDA could approve the use of the vaccine with a three-dose regimen for children under five years of age, but it is thought that it still dThey could work well for you giving sufficient protection.
Concern in the USA is growing around vaccination in children because the omicron variant is spreading rapidly and more hospitalized children have been found.
Parents of young children hope that vaccines will help provide more protection against this variant. Children under the age of 5 are the only group in the United States not authorized to receive a COVID vaccine.
Pfizer’s vaccine has been approved for children up to 5 years old, while Moderna and Johnson & Johnson’s vaccines are licensed for adults.
Pfizer has not submitted the application to the FDA, but this step is expected to happen as soon as this week. It is estimated that there 19.5 million children under 5 years of age in the United States and Puerto Rico who would benefit with the approval of this vaccine for their age group.
Read more: The mental health of minors must be encouraged from home
#USA #authorize #Pfizers #vaccine #Covid19 #children